India bans sale and manufacturing of tobacco products.

Sep.06.2022
India bans sale and manufacturing of tobacco products.
India's health ministry bans the sale and use of all tobacco and nicotine products under the Food Safety and Standards Act.

The Ministry of Health has announced a complete ban on the sale, manufacturing, distribution, or use of all tobacco and nicotine-containing products, including Gutkha, Pan Masala, Chhap Tobacco, Pure Tobacco, Kaini, Zarda, and Flavoured and flavoured tobacco, in accordance with the Food Safety and Standards Act of 2006, to protect public interest.


In a notice, V Vumlumang, the Food Safety Commissioner and Deputy Secretary General for Health and FW, stated that products containing tobacco and nicotine are harmful to human health. In accordance with regulations from the 2011 "Food Safety and Standards (Prohibition and Restriction on Sales) Act," the sale of consumer products containing tobacco and nicotine as ingredients is prohibited.


In a recent ruling, India's Supreme Court stated that manufacturers are selling a product called pan masala (tobacco-free chewable tobacco) packaged in separate small packets with added spices in order to circumvent a ban on the sale of gutka. However, these products are typically sold together by the same supplier from the same place, allowing consumers to purchase both pan masala and spicy chewable tobacco and mix them together for consumption.


Therefore, the Supreme Court has instructed relevant legal institutions to comply with the legal authorization of the Food Safety and Standards (Prohibition and Restriction of Sales) Regulation 2.3.4 in 2011, and has directed all state and federal territory health ministers to ensure full compliance with the ban on the manufacture and sale of gutkha and pan masala containing tobacco and/or nicotine.


He reported that in order to protect public health, Manipur would ban the manufacture, storage, distribution, or sale of gutka and pan masala for a period of one year.


Statement


This article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the article's contents. The translation of this article is only intended for internal industry research and communication purposes.


Due to the limitations in translation proficiency, the translated article may not fully express the original text. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macao, Taiwan, and foreign statements and positions.


Copyright of compiled information belongs to the original media and authors. If infringement occurs, please contact for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA nicotine pouch review delay report knocks tobacco shares lower
FDA nicotine pouch review delay report knocks tobacco shares lower
After Reuters reported before the market open that FDA reviews of nicotine pouch applications could face delays, shares of Philip Morris International, Turning Point Brands and British American Tobacco fell on April 1, underscoring the direct impact of U.S. regulatory signals on major tobacco companies and nicotine pouch expectations.
Apr.02
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17
NACS Urges USTR to Address Illegal E-Cigarette Exports in China Trade Engagements
NACS Urges USTR to Address Illegal E-Cigarette Exports in China Trade Engagements
NACS submitted a comment letter to USTR in a proceeding examining unfair trade practices worldwide. The letter focuses on illicit nicotine products made in China and shipped to the United States in violation of U.S. law. NACS said the U.S. electronic nicotine delivery systems market has become dominated by illicit products, mainly disposable e-cigarettes manufactured in China and sold without the marketing authorization required by the U.S. Food and Drug Administration.
Apr.16 by 2FIRSTS.ai
 Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift
Zyn Emerges as MAGA Cultural Symbol Amid FDA Policy Shift
According to The Wall Street Journal, nicotine pouch brand Zyn has rapidly gained popularity across the Trump administration and conservative political circles, including among U.S. Health Secretary Robert F. Kennedy Jr.
Business
May.20
FDA Says It Will Not Take Enforcement Action Against Zone Nicotine Pouches Until Lawsuit Is Resolved
FDA Says It Will Not Take Enforcement Action Against Zone Nicotine Pouches Until Lawsuit Is Resolved
The U.S. Food and Drug Administration has told vape manufacturer Fontem US that it does not presently intend to take enforcement action against the company’s Zone nicotine pouches while litigation over the agency’s handling of the application remains unresolved.
Apr.07 by 2FIRSTS.ai
Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japanese Tobacco (JT) reports Q1 2026 revenue of 924 billion yen, a 15.2% increase; operating profit rises 24.7%.
May.08 by 2FIRSTS.ai